KORTUC is a pioneering startup that operates in the healthcare sector, specifically focusing on cancer treatment. The company has developed an innovative solution to address hypoxia, a fundamental issue in cancer that involves a lack of oxygen reaching the tissues. This is a significant breakthrough as hypoxia often makes tumors resistant to radiotherapy, a common cancer treatment.

KORTUC's solution is a radiosensitizer, primarily composed of H2O2 (hydrogen peroxide), which is injected directly into the tumor. This radiosensitizer eliminates hypoxia, making the tumor more sensitive to radiotherapy. In simple terms, it boosts the effectiveness of radiotherapy, providing a more potent option for cancer treatment.

The company's research and development efforts have been recognized in reputable publications such as "Cancer Science" and "Oncology Letters". This suggests that KORTUC is at the forefront of cancer research, contributing to the advancement of treatment options.

KORTUC's business model revolves around the development and commercialization of its innovative radiosensitizer. The company's primary clients are healthcare providers who administer radiotherapy to cancer patients. By offering a solution that enhances the effectiveness of existing treatments, KORTUC is positioned to generate revenue through the sale of its product.

Looking ahead, KORTUC plans to continue its research and development activities to further refine its product and potentially develop new solutions. The company's team, composed of its founding members and other professionals, is dedicated to fulfilling its mission of providing more options for cancer radiotherapy.

Keywords: Cancer Treatment, Hypoxia, Radiotherapy, Radiosensitizer, H2O2, Healthcare Providers, Cancer Research, Innovative Solution, Product Commercialization, Research and Development.